Although HbA~1c~ is widely used for diagnosis and management of diabetes in clinical practice and research studies, management of the incidental detection of hemoglobin variants (e.g., hemoglobin S \[HbS\], HbC) by common HbA~1c~ methods, such as ion exchange high-performance liquid chromatography (HPLC), is not well established. Many clinical laboratories do not report the presence of hemoglobin variants, whereas others report them only if they interfere with HbA~1c~ measurement ([@B1]). As routine HbA~1c~ testing may incidentally yield information regarding hemoglobin variants that can affect clinical care, planning for appropriate management is warranted.

The Vitamin D and Type 2 Diabetes (D2d) Study is a multicenter, randomized, placebo-controlled trial testing whether vitamin D supplementation reduces diabetes incidence in people at high risk ([@B2]). Adults meeting at least two of the three criteria for prediabetes established in 2010 by the American Diabetes Association are eligible for enrollment, and a racially and ethnically diverse study population is sought to ensure generalizability of results. HbA~1c~ testing is performed using an HPLC method (Tosoh G8, Tosoh Bioscience, South San Francisco, CA) at the University of Vermont's Laboratory for Clinical Biochemistry Research. Review of chromatograms can reveal unexpected peaks reflecting the presence of hemoglobin variants. Although HbS and HbC do not interfere with the assay, the presence of other variants, such as HbE, precludes reporting of HbA~1c~ results. When an abnormal peak is seen, hemoglobin electrophoresis is performed to identify the hemoglobin variant. Because reporting of incidentally detected hemoglobin variants is not standardized, D2d investigators sought consultative opinions from colleagues in medical genetics and hematology/oncology, the study's Data and Safety Monitoring Board, and the University of Vermont Medical Center's Ethics Committee (Consultative Subcommittee).

As of 31 May 2016, 4,360 volunteers had undergone HbA~1c~ testing, of whom, 1,136 were black or African American. Overall, 98 participants (2.2%) had a hemoglobin variant detected ([Table 1](#T1){ref-type="table"}). Among the 95 affected volunteers who were black or African American, 78.9% had the HbS trait, 17.9% had the HbC trait, and 3.2% had other variants. The percentages of D2d participants with HbS and HbC are in keeping with those previously reported ([@B3]).

###### 

Variant hemoglobins by race/ethnicity

                                      *n*     Variant Hb   HbS        HbC        Other[\*](#tblfn2){ref-type="table-fn"}
  ----------------------------------- ------- ------------ ---------- ---------- -----------------------------------------
  Race                                                                           
   Black or African American          1,136   95 (8.4)     75 (6.6)   17 (1.5)   3 (0.3)
   Asian                              182     0            0          0          0
   American Indian/Alaska Native      21      1 (4.8)      1 (4.8)    0          0
   Native Hawaiian/Pacific Islander   10      0            0          0          0
   White                              2,920   1 (0.03)     1 (0.03)   0          0
   Other                              91      1 (1.1)      1 (1.1)    0          0
  Ethnicity                                                                      
   Hispanic                           448     4 (0.9)      3 (0.7)    1 (0.2)    0
   Non-Hispanic                       3,912   94 (2.4)     75 (1.9)   16 (0.4)   3 (0.08)
  Total                               4,360   98 (2.2)     78 (1.8)   17 (0.4)   3 (0.07)

Data are *n* or *n* (%).

Other hemoglobin variants included elevated hemoglobin F (*n* = 1) and probable HbE trait (*n* = 2).

As hemoglobin variant detection is an intrinsic part of HbA~1c~ testing by HPLC (i.e., an "anticipatable" incidental finding, in the parlance of the Presidential Commission for the Study of Bioethical Issues), planning for the handling of this information was indicated. A key consideration favoring notification is that people may use knowledge of their hemoglobin variant carrier status in reproductive decision making to modify risk for offspring of serious conditions such as sickle cell disease ([@B4]). Knowledge of carrier status may also potentially provide direct health benefit to carriers. For example, among African Americans, HbS trait is associated with an increased risk of chronic kidney disease. Furthermore, some hemoglobin variants may alter red blood cell half-life, which could affect the accuracy and interpretation of HbA~1c~ levels.

Given these considerations, along with the relatively low risk associated with disclosing the finding (e.g., subsequent recognition of misattributed paternity), we determined that notifying participants was appropriate. Consequently, D2d investigators developed a plan for handling the incidental detection of hemoglobin variants. Single-page informational handouts on the two most common variants (HbS and HbC) briefly introduce the topic, suggest that the participant may want to share the finding with his or her primary care provider, and note that meeting with a genetic counselor could be considered if the participant is thinking of having children. A D2d staff member notifies the participant at the next study visit, and the relevant informational handout is shared and discussed. Notification, while occasionally eliciting surprise, has not yielded negative feedback from staff or affected participants.

Many clinical laboratories use HPLC assays for HbA~1c~ and elect not to report hemoglobin variants ([@B1]). Likely underlying this practice is the generally asymptomatic nature of carrier status. Additionally, many clinical providers are unaware that hemoglobin variants may be detected incidentally during HbA~1c~ testing ([@B5]) and may not be prepared to discuss such findings. Our approach to notification may be generalizable to clinical settings. Although we generated study-specific materials for distribution (available at <http://www.d2dstudy.org/hemoglobin-variant>), the National Institute of Diabetes and Digestive and Kidney Diseases has developed online resources on this topic for providers and affected individuals. As the detection of hemoglobin variants when measuring HbA~1c~ by HPLC is foreseeable and is common in racially diverse populations, this occurrence should be anticipated and requires a plan for appropriate management in clinical medicine and research.
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